Sanofi's Sarclisa Subcutaneous Formulation Achieves Co-Primary Endpoints In IRAKLIA Phase 3 Trial For Multiple Myeloma Treatment
Sanofi's Sarclisa Subcutaneous Formulation Achieves Co-Primary Endpoints In IRAKLIA Phase 3 Trial For Multiple Myeloma Treatment
賽諾菲安萬特的Sarclisa皮下製劑在治療多發性骨髓瘤的IRAKLIA三期試驗中達成共同主要終點。
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
新的Sarclisa皮下製劑在多發性骨髓瘤的IRAKLIA三期研究中達到了共同主要終點
- Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV
- IRAKLIA is the first global phase 3 study to evaluate the SC administration of a cancer treatment via an OBDS
- OBDS is an alternative delivery method designed to improve the patient experience and currently available SC administration
- 將Sarclisa SC製劑添加到Pd中用於R/R Mm的治療，在IRAKLIA三期研究中達到了共同主要終點，證明其與Sarclisa IV的非劣性
- IRAKLIA是第一個評估通過OBDS進行癌症治療的皮下給藥的全球三期研究
- OBDS是一種替代給藥方法，旨在改善患者體驗，當前可使用的皮下給藥方式
資訊熱榜
更新時間